The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.
Tag Archive for: kinase inhibitor
Merck & Co. Inc. and Eisai Co. Ltd. said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.